Page 132 - 《中国药房》2022年9期

ment therapy：systematic review and Monte Carlo simula- hemofiltration in the military health system[J]. J Clin Phar-
tions[J]. Ren Replace Ther，2021，7：61. macol，2021，61（9）：1182-1194.
[23] LI Z，BAI J，WEN A P，et al. Pharmacokinetic and phar- [34] LI S W，XIE F F. Population pharmacokinetics and simula-
macodynamic analysis of critically ill patients undergoing tions of imipenem in critically ill patients undergoing con-
continuous renal replacement therapy with imipenem[J]. tinuous renal replacement therapy[J]. Int J Antimicrob
Clin Ther，2020，42（8）：1564-1577.e8. Agents，2019，53（1）：98-105.
[24] FISH D N，TEITELBAUM I，ABRAHAM E. Pharmacoki- [35] COTA J M，FAKHRIRAVARI A，ROWAN M P，et al. In-
netics and pharmacodynamics of imipenem during conti- travenous antibiotic and antifungal agent pharmacokine-
nuous renal replacement therapy in critically ill patients tic-pharmacodynamic dosing in adults with severe burn
[J]. Antimicrob Agents Chemother，2005，49（6）：2421-2428. injury[J]. Clin Ther，2016，38（9）：2016-2031.
[25] TROTMAN R L，WILLIAMSON J C，SHOEMAKER D [36] NAPP L C，ZIEGELER S，KINDGEN-MILLES D. Ratio-
M，et al. Antibiotic dosing in critically ill adult patients nale of hemoadsorption during extracorporeal membrane
receiving continuous renal replacement therapy[J]. Clin oxygenation support[J]. Blood Purif，2019，48（3）：203-
Infect Dis，2005，41（8）：1159-1166. 214.
[26] LEWIS S J，KAYS M B，MUELLER B A. Use of Monte [37] GOMEZ F，VEITA J，LAUDANSKI K. Antibiotics and
Carlo simulations to determine optimal carbapenem do- ECMO in the adult population-persistent challenges and
sing in critically ill patients receiving prolonged intermit- practical guides[J]. Antibiotics（Basel），2022，11（3）：338.
tent renal replacement therapy[J]. J Clin Pharmacol，2016， [38] CHEN W Q，ZHANG D，LIAN W W，et al. Imipenem
56（10）：1277-1287. population pharmacokinetics：therapeutic drug monitoring
[27] WEN A P，LI Z，YU J X，et al. Clinical validation of thera- data collected in critically ill patients with or without ex-
peutic drug monitoring of imipenem in spent effluent in tracorporeal membrane oxygenation[J]. Antimicrob Agents
critically ill patients receiving continuous renal replace- Chemother，2020，64（6）：e00385-e00320.
ment therapy：a pilot study[J]. PLoS One，2016，11（4）： [39] WELSCH C，AUGUSTIN P，ALLYN J，et al. Alveolar
e0153927. and serum concentrations of imipenem in two lung trans-
[28] TEGEDER I，BREMER F，OELKERS R，et al. Pharmaco- plant recipients supported with extracorporeal membrane
kinetics of imipenem-cilastatin in critically ill patients un- oxygenation[J]. Transpl Infect Dis，2015，17（1）：103-105.
dergoing continuous venovenous hemofiltration[J]. Anti- [40] JARURATANASIRIKUL S，VATTANAVANIT V，
microb Agents Chemother，1997，41（12）：2640-2645. WONGPOOWARAK W，et al. Pharmacokinetics and
[29] MUELLER B A，SCARIM S K，MACIAS W L. Compari- Monte Carlo dosing simulations of imipenem in critically
son of imipenem pharmacokinetics in patients with acute ill patients with life-threatening severe infections during
or chronic renal failure treated with continuous hemofiltra- support with extracorporeal membrane oxygenation[J].
tion[J]. Am J Kidney Dis，1993，21（2）：172-179. Eur J Drug Metab Pharmacokinet，2020，45（6）：735-747.
[30] KELLER E，FECHT H，BÖHLER J，et al. Single-dose ki- [41] YOSHIZAWA K，IKAWA K，IKEDA K，et al. Population
netics of imipenem/cilastatin during continuous arteriove- pharmacokinetic-pharmacodynamic target attainment analy-
nous haemofiltration in intensive care patients[J]. Nephrol sis of imipenem plasma and urine data in neonates and
Dial Transplant，1989，4（7）：640-645. children[J]. Pediatr Infect Dis J，2013，32（11）：1208-
[31] JESCHKE M G，VAN BAAR M E，CHOUDHRY M A， 1216.
et al. Burn injury[J/OL]. Nat Rev Dis Primers，2020[2022- [42] DAO K，FUCHS A，ANDRÉ P，et al. Dosing strategies of
02-23]. https：//www.researchgate.net/publication/339236767 imipenem in neonates based on pharmacometric model-
Burn_injury. DOI：10.1038/s41572-020-0145-5. ling and simulation[J]. J Antimicrob Chemother，2022，77
[32] GOMEZ D S，SANCHES-GIRAUD C，SILVA C V Jr， （2）：457-465.
et al. Imipenem in burn patients：pharmacokinetic profile [43] DONG L，ZHAI X Y，YANG Y L，et al. Population phar-
and PK/PD target attainment[J]. J Antibiot（Tokyo），2015， macokinetics and dosing optimization of imipenem in chil-
68（3）：143-147. dren with hematological malignancies[J]. Antimicrob
[33] POR E D，AKERS K S，CHUNG K K，et al. Population Agents Chemother，2019，63（6）：e00006-e00019.
pharmacokinetic modeling and simulations of imipenem （收稿日期：2022-01-29 修回日期：2022-04-08）
in burn patients with and without continuous venovenous （编辑：唐晓莲）

·1146 · China Pharmacy 2022 Vol. 33 No. 9 中国药房 2022年第33卷第9期